Fatty Liver Disease in Young Indians

Fatty Liver Disease in Young Indians

Why in News?

According to a recent research published in The Indian Express, Dr. Soin and his team found that nearly 50% of prospective liver donors aged 20–40 had fatty liver disease.

What is Fatty Liver Disease (FLD)?

• About: Fatty Liver Disease (FLD), medically called hepatic steatosis, occurs when excess fat accumulates in liver cells.
  • Small amounts of liver fat are normal, fat exceeding roughly 5–10% of liver weight is considered abnormal and can impair liver function.
• Types: The two principal forms are Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), linked to metabolic disorders, and Alcohol-Associated Liver Disease (ALD), caused by excessive alcohol intake. 
• Risk Factors: Major risk factors include obesity, insulin resistance, type 2 diabetes, high triglycerides, high cholesterol, metabolic syndrome, and heavy alcohol consumption.
  • Sedentary lifestyles significantly increase risk.
• Development Process: The disease develops when the liver receives or produces more fat than it can process and remove.
  • Excess fat accumulates within liver cells, disrupting metabolism. It can cause liver-cell injury and inflammation, transforming a relatively benign condition into progressive liver disease.
• Stages of Progression: The progression typically follows four stages: simple steatosis, steatohepatitis (MASH/ASH), fibrosis, and finally cirrhosis. Each stage reflects increasing structural damage and declining liver health.
• Symptoms: Most patients remain asymptomatic for years. When symptoms occur, they commonly include fatigue, weakness, mild abdominal discomfort, and right-upper abdominal pain.
  • Advanced disease may cause abdominal swelling, leg edema, easy bruising, confusion, dark urine, and jaundice, indicating significant liver dysfunction.
• Complications: Untreated fatty liver can progress to cirrhosis, liver failure, portal hypertension, and liver cancer. It is also strongly associated with elevated cardiovascular and metabolic risks.
• Diagnosis: Diagnosis relies on liver enzyme tests, ultrasound, CT, MRI, elastography, and occasionally liver biopsy.
  • Doctors may use FibroScan to evaluate liver stiffness. 
  • Doctors utilize blood scores like FIB-4 or ELF tests to quantify the likelihood of advanced fibrosis.
• Treatment: Losing 3% to 10% of total body weight can significantly reduce both liver fat and localized inflammation.
  • Medical therapies with targeted treatments like resmetirom (Rezdiffra) and semaglutide approved to treat moderate to severe liver scarring. 
  • Omega-3 fatty acids and Vitamin E are also utilized under professional medical guidance to improve liver health.
  • Tirzepatide is a dual action medicine. It drives powerful weight loss by suppressing appetite and slowing digestion, and stabilizes blood sugar.
  • GLP-1s are highly effective weight-loss medications that mimic the naturally occurring GLP-1 hormone.
  • FGF21 (Fibroblast Growth Factor 21) drugs are a class of engineered therapeutic hormones that enhance metabolic health. 

Rising Burden of Fatty Liver Disease Among Young Indians

• Indian Prevalence: A recent Lancet-backed study reveals an alarming 38.9% MASLD prevalence among adults in 27 Indian cities.
  • It affects nearly four out of ten individuals nationwide.
  • The Phenome India cohort found significant liver fibrosis in 2.4% of adults overall. 
  • Approximately 4% to 6.3% of MASLD patients screened already showed evidence of significant liver fibrosis.
  • Cities like Roorkee and Bhopal have recorded rates approaching nearly 50%, whereas cities like Thiruvananthapuram sit closer to 27%.
• Youth Risk: Among young South Indian adults aged 18–30 years, data reveals that 27.4% have MASLD. This group exhibits a high transaminitis rate of 25.9%.
  • Approximately 15% of Indian MASLD patients have normal body weight. This distinct “lean MASLD” phenotype is driven by high visceral fat.
  • The pooled prevalence of NAFLD among Indian children is 35.4%. This figure escalates drastically to 63.4% within obese pediatric cohorts.
• Global Comparison: India’s fatty liver burden has surged above 23% since 1990. High fasting blood sugar (diabetes/prediabetes) is the primary trigger in India.
  • Global cases have skyrocketed, with total prevalent cases crossing the 1.3 billion mark, marking a staggering 143% increase since 1990.
  • Medical consensus from The Lancet projects global cases could reach up to 2 billion by 2050 if current metabolic and dietary trends are not reversed.
• Gender Disparity: Young males show a higher prevalence than females. A pediatric interim analysis reports an 8.7% prevalence with significant male predominance.
  • In clinical studies focusing on children with obesity, prevalence estimates can jump to 30% to 50%, maintaining a male-to-female ratio of roughly 2:1.
  • Estrogen is believed to have a protective effect on the liver, whereas androgens (such as testosterone) may exacerbate fat accumulation and metabolic risk.
• Diabetes Link: The MASLD prevalence spikes to 68.2% among Type 2 diabetes patients.
  • High blood sugar and insulin resistance trigger this by causing “lipotoxicity”.
• Sedentary Habits: Prolonged sitting of 8 to 12 hours actively decreases your NEAT (Non-Exercise Activity Thermogenesis) and blunts your body’s ability to process blood sugar.
  • WHO mandates that adults must get at least 150 to 300 minutes of moderate-intensity aerobic physical activity (or 75 to 150 minutes of vigorous activity) per week.
  • Studies show that a staggering number of urban Indians do not meet the baseline 150-minute weekly exercise threshold.